In the present work, we show that long-term oral administration of the dual FXR/ membrane G protein-coupled receptor (TGR5) agonist INT-767 prevents HCC formation in Abcb4−/− and not in Fxr−/− mice. This evidence concerns the gene NR1H4 and hepatocellular carcinoma.